Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT® in brain cancer patients

Contributed by: PR Newswire

Tags

CurasightAnnouncement

More Like This

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

Positive results from the Phase II study of uTRACE in brain cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague

Curasight A/S Achieves First Milestone under collaboration with Curium Inc.

Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy

Curatis on track: submission of orphan drug designation application in the US for lead product candidate

Business Wire logo

Curatis will apply for a Biologic License for C-PTBE-01 in the USA - this will significantly increase the duration of market protection in the USA in the event of approval

Tilray Medical Supports New Clinical Trial to Study Medical Cannabis in Glioblastoma Cancer Treatment

Business Wire logo

Curatis discloses Corticorelin as active substance of C-PTBE-01